Bioavailability enhancement of baclofen by gastroretentive floating formulation: Statistical optimization, in vitro and in vivo pharmacokinetic studies

Drug Development and Industrial Pharmacy

Volumn 39, Issue 6, 2013, Pages 880-888

  Thakar, Krishna ^a   Joshi, Garima ^a   Sawant, Krutika K ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Baclofen; Factorial design; Floating tablet; Gastroretentive; Pharmacokinetics

Indexed keywords

BACLOFEN;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HARDNESS; IN VITRO STUDY; IN VIVO STUDY; SUSTAINED DRUG RELEASE; TABLET; TABLET FORMULATION; THICKNESS; VISCOSITY;

ANIMALS; BACLOFEN; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; GASTRIC MUCOSA; HUMANS; RABBITS;

EID: 84877083086     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.709249     Document Type: Article

References (45)

1. Ponchel G, Irache J. (1998). Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev, 34:191-219.
2. Singh BN, Kim KH. (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release, 63:235-259.
3. Longer MA, Chng HS, Robinson JR. (1985). Bioadhesive polymers as platforms for oral controlled drug delivery III: Oral delivery of chlorothiazide using a bioadhesive polymer. J Pharm Sci, 74:406-411.
4. Kumar RAA, Rao CSG, Reddy PV. (2009). Formulation and evaluation of swellable and floating gastroretentiv ciprofloxacin hydrochloride Tablets. AAPS Pharm Sci Tech, 10:220-226.
5. Nagarwal RC, Ridhurkar DN, Pandit JK. (2010). In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet. AAPS PharmSciTech, 11:294-303.
6. Baumgartner S, Kristl J, Vrecer F, Vodopivec P, Zorko B. (2000). Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm, 195:125-135.
7. Menon A, Ritschel WA, Sakr A. (1994). Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci, 83:239-245.
8. Timmermans J, Moes AJ. (1994). Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: New data for reconsidering the controversy. J Pharm Sci, 83:18-24.
9. Hilton AK, Deasy PB. (1992). In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate. Int J Pharm, 86:79-88.
10. Desai S, Bolton S. (1993). A floating controlled-release drug delivery system: In vitro-in vivo evaluation. Pharm Res, 10:1321-1325.
11. Narendra C, Srinath MS, Babu G. (2006). Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention. AAPS PharmSciTech, 7:E34.
12. Cedillo-Ramirez E, Villafuerte-Robles L, Hernandez-Leon A. (2006). Effect of added Pharmatose DCL11 on the sustainedrelease of metronidazole from Methocel K4M and Carbopol 971P NF floating matrices. Drug Dev Ind Pharm, 32:955-965.
13. Sheth PR, Tossounian J. (1984). The hydrodynamically balanced system (HBSTM): A novel drug delivery system for oral use. Drug Dev Ind Pharm, 10:313-339.
14. Xiaoqiang X, Minjie S, Feng Z, Yiqiao H. (2006). Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: In vitro and in vivo evaluation in healthy volunteers. Int J Pharm, 310:139-145.
15. Shuang H, Feng L, Dan Z, Junrong D, Yuan H. (2011). Formulation and evaluation of novel coated floating tablet of bergenin and cetirizine dihydrochloride for gastric delivery. Drug Dev Ind Pharm, 1-9. DOI: 10.3109/03639045.2011.645836.
16. Varshosaz J, Tavakoli N, Roozbahani F. (2006). Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv, 13:277-285.
17. Efentakis M, Peponaki C. (2008). Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on Carbopols with isosorbite mononitrate. AAPS PharmSciTech, 9:917-923.
18. Al-Zoubi NM, AlKhatib HS, Obeidat WM. (2011). Evaluation of hydrophilic matrix tablets based on Carbopol(R) 971P and lowviscosity sodium alginate for pH-independent controlled drug release. Drug Dev Ind Pharm, 37:798-808.
19. Prajapati ST, Patel LD, Patel CN. (2009). Floating matrix tablets of domperidone: Formulation and optimization using simplex lattice design. Thai J Pharm Sci, 33:113-122.
20. Rades T, Mueller-Goymann CC. (1998). Interactions between fenoprofen sodium and poly (ethylene oxide). Eur J Pharm Biopharm, 46:51-59.
21. Wise J, Conklin JL. (2004). Gastroesophageal reflux disease and baclofen: Is there a light at the end of the tunnel? Curr Gastroenterol Rep, 6:213-219.
22. Martindale. (2005). The complete drug reference. 33rd ed. Chicago, IL: Pharmaceutical Press, 1758-1759.
23. United States Pharmacopoeia and National Formulary (USP 30 NF 25). (2007). United States Pharmacopoeial Convention. Rockville, MD: 1482-1483.
24. Ahuja, S. (1985). Baclofen. In: Florey K, ed. Analytical Profiles of Drug Substances and Excipients. London, UK: Academic Press, 527-548.
25. Merino M, Peris-Ribera JE, Torres-Molina F, Sanchez-Pico A, Garcia-Carbonell MC, Casabo VG et al. (1989). Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. Biopharm Drug Dispos, 10:279-297.
26. Bolton S, Bon C. (1997). Pharmaceutical statistics: Practical and clinical applications. 3rd ed. New York: Marcel Dekker In, 217-241.
27. Roy P, Shahiwala A. (2009). Statistical optimization of ranitidine HCl floating pulsatile delivery system for chronotherapy of nocturnal acid breakthrough. Eur J Pharm Sci, 37:363-369.
28. Hintze J.(2004). NCSS and PASS. Number cruncher statistical systems. Kaysville, Utah.
29. Box GEP, Wilson KB. (1951). On the experimental attainment of optimum conditions. J R Stat Soc B, 13:1-45.
30. Jimenez-Castellano RM, Zia H, Rhodes T. (1994). Design and testing in vitro of a bioadhesive and a floating drug delivery for oral application. Int J Pharm, 105:65-70.
31. Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. (2005). Oral sustained delivery of atenolol from floating matrix tablets-formulation and in vitro evaluation. Drug Dev Ind Pharm, 31:367-374.
32. Gohel MC, Mehta, PK, Dave PR, Baria NH. (2005). More relevant dissolution method for evaluation of FDDS. Dissolution Technol, 11:22-25.
33. Lamoudi L, Chaumeil JC, Daoud K. (2012). Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M. Drug Dev Ind Pharm, 38:515-520.
34. Sahoo AK, Singh SK, Varma A. (2011). Formulation development of buoyant controlled release tablets containing chitosan: Optimization of in vitro dissolution and release kinetics. Int J Pharm Pharm Sci, 3:81-85.
35. Ozdemir N, Ordu S, Ozkan Y. (2000). Studies of floating dosage forms of furosemide: In vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev Ind Pharm, 26:857-866.
36. Millerioux L, Brault M, Gualano V, Mignot A. (1996). Highperformance liquid chromatographic determination of baclofen in human plasma. J Chromatogr A, 729:309-314.
37. Liandong H, Xun Yang L, Wei L, Jianxue Y, Yanhong J, Chuang S, Hongxin X. (2011). Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: In vitro and in vivo evaluation in healthy volunteers. Eur J Pharm Sci, 42:99-105.
38. Dev RK, Bali V, Pathak K. (2011). Novel microbially triggered colon specific delivery system of 5-Fluorouracil: Statistical optimization, in vitro, in vivo, cytotoxic and stability assessment. Int J Pharm, 411:142-151.
39. Indian Pharmacopoeia. (2007). Ministry of health and family welfare, Indian pharmacopoeia commission, Ghaziabad, India, 2150-2153.
40. Efentakis M, Naseef H, Vlachou M. (2010). Two- and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs. Drug Dev Ind Pharm, 36:903-916.
41. Armstrong, AN, James, KC. (1996). Pharmaceutical experimental design and interpretation. 2nd ed. Bristol, PA: Taylor and Francis Publishers, 131-192.
42. Adinarayana K, Ellaiah P. (2002). Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci, 5:272-278.
43. Siepmann J, Peppas NA. (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev, 48:139-157.
44. Mostafavi A, Emami J, Varshosaz J, Davies NM, Rezazadeh M. (2011). Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: Pharmacokinetic characterization in healthy human volunteers. Int J Pharm, 409:128-136.
45. Dhawan S, Dhawan K, Varma M, Sinha VR. (2005). Application of poly (ethylene oxide) in drug delivery systems. Pharm Technol, 29:72-80.